COMMUNIQUÉS West-GlobeNewswire

Travere Therapeutics Reports First Quarter 2024 Financial Results

06/05/2024 - 22:01

FDA grants Priority Review for sNDA to convert FILSPARI ® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 Received 511 new [...]

Assertio Reports First Quarter 2024 Financial Results

06/05/2024 - 22:01

First Quarter Net Product Sales of $31.9 Million Rolvedon Growth Continues, with $14.5 million in Net Product Sales $7.5 Million in Cash Flow from Operations Increases Cash to $80.7 Million LAKE FOREST, Ill., May 06, [...]

Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update

06/05/2024 - 22:01

- Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - - Enrollment completed [...]

The Association of American Physicians and Surgeons (AAPS) Files Brief in the Ohio Supreme Court to Defend Children against Transgender Operations

06/05/2024 - 21:33

TUCSON, Ariz., May 06, 2024 (GLOBE NEWSWIRE) -- The Association of American Physicians and Surgeons (AAPS) has filed an amicus brief in the Supreme Court of Ohio to defend children against transgender operations. The [...]

HEALWELL AI Inc. Announces Upsize of Bought Deal to Up to $20 Million

06/05/2024 - 21:17

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- HEALWELL AI INC. (“ HEALWELL ” or the “ Company ”) (TSX: AIDX) is pleased to [...]

Trading in Novo Nordisk shares by board members, executives and associated persons

06/05/2024 - 21:02

Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with [...]

Novo Nordisk A/S - share repurchase programme

06/05/2024 - 20:44

Bagsværd, Denmark, 06 May 2024 – The execution of Novo Nordisk A/S’ overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase [...]

Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme

06/05/2024 - 20:40

Bagsværd, Denmark, 06 May 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 5,427,801,225.00 million from Novo Holdings A/S. The transaction is [...]

NMDP’s Amy Ronneberg Recognized as Most Admired CEO by Minneapolis/St. Paul Business Journal

06/05/2024 - 20:17

MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- NMDP SM , a global nonprofit leader in cell therapy, announced today that the Minneapolis / St. Paul Business Journal named CEO Amy Ronneberg to its 2024 list of Most [...]

Bondholders approve amended terms of the 2024 convertible bonds

06/05/2024 - 18:35

Ad hoc announcement pursuant to Art. 53 LR Bondholders approve amended terms of the 2024 convertible bonds The proposed amendments to the terms of the 2024 convertible bond have been approved by the bondholders and will [...]

ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024

06/05/2024 - 18:03

Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD) Company planning to request an End-of-Phase II meeting with the FDA to discuss plans for a registrational [...]

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

06/05/2024 - 18:00

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]

Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

06/05/2024 - 18:00

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]

Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD

06/05/2024 - 18:00

` Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD Leuven, BELGIUM – May 6, 2024 – 6:00 PM CET , Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based [...]

Nicox’s Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024

06/05/2024 - 17:46

Press Release Nicox’s Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 Shareholders adopted all resolutions proposed by the Board of Directors at the Ordinary and Extraordinary General Meetings May 6, [...]

Nicox : assemblée générale ordinaire et extraordinaire du 6 mai 2024

06/05/2024 - 17:46

Communiqué de presse Nicox : assemblée générale ordinaire et extraordinaire du 6 mai 2024 Les actionnaires ont adopté toutes les résolutions à titre ordinaire et à titre extraordinaire agréées par le Conseil d’ [...]

Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine

06/05/2024 - 17:16

Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo Cytisinicline treatment well tolerated with no serious adverse events reported and [...]

IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024

06/05/2024 - 17:00

LAWRENCEVILLE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces [...]

Transactions in Connection with Share Buy-back Program

06/05/2024 - 16:01

Company Announcement COPENHAGEN, Denmark; May 6, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The [...]